Sequencing tests to characterize cancers
Invested July 22
Genexpath is designing next-generation diagnostic tests to better characterize cancers such as lymphomas and sarcomas. Better characterizing cancers means knowing them better and treating them better.
LymphoSign test and SarcomaFusion test Both are based on an innovative technique that has been the subject of several publications in scientific journals with a high impact factor and has been the source of four patent applications. The technique has already been well proven.
These kits are used on tumoral RNA taken by biopsy from the patient. The innovation lies in the fact that the amount of RNA required is very low. For sarcoma, a needle biopsy, which is less invasive, is sufficient to allow the fusion transcripts detection.
Genexpath kits allow much faster and much cheaper analysis than more traditional methods.
Finally, the tests showed that it was possible to detect cases that remained undetected by conventional techniques.